Business Of Biotech
BoB@JPM: Kasper Roet, Ph.D., QurAlis
Mar 17, 2025
Kasper Roet, Ph.D., is the founder and CEO of QurAlis, a biotech innovator focused on genetic medicines for ALS. In this fascinating conversation, he discusses his journey from the Dutch Brain Bank to leading a consortium aimed at reforming the conservative FDA regulations that are driving clinical trials offshore. Roet emphasizes the critical need for a flexible approach to expedite therapy approvals and shares insights on the advancements in genetic medicine since the first ALS gene was discovered.
43:46
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Dr. Kasper Roet emphasizes the importance of collaborative efforts among biotechs to advocate for necessary regulatory reforms in genetic medicine.
- Curalis's innovative clinical programs target specific genetic mechanisms in ALS, highlighting the potential for early intervention in preserving motor neuron health.
Deep dives
Dr. Casper Root's Transition from IT to Life Sciences
Dr. Casper Root began his career in Information Technology where his passion for computers led him to establish an IT company during the internet boom, highlighting his entrepreneurial spirit. Although he initially excelled in IT, his strong desire to contribute to medicine and develop therapies for diseases guided his pivot toward life sciences. He returned to study medical biology and later pursued a master's in neuroscience, which deepened his commitment to understanding and combating neurological disorders. His hands-on experience, particularly in gene therapy focused on spinal cord repair, solidified his goal of developing impactful therapies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
